| Eligibility |
Inclusion Criteria:
- Access to a participating HIV Vaccine Trials Network (HVTN) clinical research site
(CRS) and willingness to be followed for the planned duration of the study
- Ability and willingness to provide informed consent
- Assessment of understanding: participant demonstrates understanding of this study;
completes a questionnaire prior to first vaccination with verbal demonstration of
understanding of all questionnaire items answered incorrectly
- Willing to be contacted annually after completion of scheduled clinic visits for a
total of 3 years following initial study injection
- Agrees not to enroll in another study of an investigational research agent before the
last required protocol clinic visit
- Good general health as shown by medical history, physical exam, and screening
laboratory tests
- Willingness to receive HIV test results
- Willingness to discuss HIV infection risks, amenable to HIV risk reduction counseling,
and committed to maintaining behavior consistent with low risk of HIV exposure through
the last required protocol clinic visit
- Assessed by the clinic staff as being at "low risk" for HIV infection
- Hemoglobin greater than or equal to 11.0 g/dL for participants who were born female,
greater than or equal to 13.0 g/dL for volunteers who were born male
- White blood cell count equal to 3,300 to 12,000 cells/mm^3
- Total lymphocyte count greater than or equal to 800 cells/mm^3
- Remaining differential either within institutional normal range or with site physician
approval
- Platelets equal to 125,000 to 550,000/mm^3
- Chemistry panel: alanine aminotransferase (ALT) less than 1.25 times the institutional
upper limit of normal (IULN) and creatinine less than or equal to IULN.
- Negative HIV-1 and -2 blood test: U.S. participants must have a negative FDA-approved
enzyme immunoassay (EIA). Non-U.S. sites may use locally available assays that have
been approved by HVTN Laboratory Operations.
- Negative hepatitis B surface antigen (HBsAg)
- Negative anti-hepatitis C virus (anti-HCV) antibodies (Abs), or negative HCV
polymerase chain reaction (PCR) if the anti-HCV is positive
- Normal urine: negative urine glucose, negative or trace urine protein, and negative or
trace urine hemoglobin (if trace hemoglobin is present on dipstick, a microscopic
urinalysis with red blood cells levels within institutional normal range)
- Participants who were born female: negative serum or urine beta human chorionic
gonadotropin (ß-HCG) pregnancy test performed prior to vaccination on the day of
initial vaccination
- A participant who was born female must: agree to consistently use effective
contraception for sexual activity that could lead to pregnancy from at least 21 days
prior to enrollment through the last required protocol clinic visit. (More information
on this criterion can be found in the protocol); OR not be of reproductive potential,
such as having reached menopause (no menses for 1 year) or having undergone
hysterectomy, bilateral oophorectomy, or tubal ligation; OR be sexually abstinent.
- Participants who were born female must also agree not to seek pregnancy through
alternative methods such as artificial insemination or in vitro fertilization until
after the last required protocol clinic visit.
Exclusion Criteria:
- Blood products received within 120 days before first vaccination
- Investigational research agents received within 30 days before first vaccination
- Body mass index (BMI) greater than or equal to 40; or BMI greater than or equal to 35
with 2 or more of the following: age greater than 45 years, systolic blood pressure
greater than 140 mm Hg, diastolic blood pressure greater than 90 mm Hg, or known
hyperlipidemia
- Intent to participate in another study of an investigational research agent before the
last required protocol clinic visit
- Pregnant or breastfeeding
- HIV vaccine(s) received in a prior HIV vaccine trial. For participants who have
received control/placebo in an HIV vaccine trial, the HVTN 102 Protocol Safety Review
Team (PSRT) will determine eligibility on a case-by-case basis.
- Non-HIV experimental vaccine(s) received within the last 5 years in a prior vaccine
trial. Exceptions may be made for vaccines that have subsequently undergone licensure
by the FDA. For participants who have received control/placebo in an experimental
vaccine trial, the HVTN 102 PSRT will determine eligibility on a case-by-case basis.
For participants who have received an experimental vaccine(s) greater than 5 years
ago, eligibility for enrollment will be determined by the HVTN 102 PSRT on a
case-by-case basis.
- Live attenuated vaccines other than influenza vaccine received within 30 days before
first vaccination or scheduled within 14 days after injection (e.g., measles, mumps,
and rubella [MMR]; oral polio vaccine [OPV]; varicella; yellow fever)
- Influenza vaccine or any vaccines that are not live attenuated vaccines and were
received within 14 days prior to first vaccination (e.g., tetanus, pneumococcal,
hepatitis A or B)
- Allergy treatment with antigen injections within 30 days before first vaccination or
that are scheduled within 14 days after first vaccination
- Immunosuppressive medications received within 168 days before first vaccination. (Not
excluded: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] topical
corticosteroids for mild, uncomplicated dermatitis; or [4] a single course of
oral/parenteral corticosteroids at doses less than 2 mg/kg/day and length of therapy
less than 11 days with completion at least 30 days prior to enrollment.
- Serious adverse reactions to vaccines including anaphylaxis and related symptoms such
as hives, respiratory difficulty, angioedema, and/or abdominal pain. (Not excluded: a
participant who had a nonanaphylactic adverse reaction to pertussis vaccine as a
child)
- Immunoglobulin received within 60 days before first vaccination
- Autoimmune disease (Not excluded: mild, well-controlled psoriasis)
- Immunodeficiency
- Untreated or incompletely treated syphilis infection
- Clinically significant medical condition, physical examination findings, clinically
significant abnormal laboratory results, or past medical history with clinically
significant implications for current health. More information on this criterion can be
found in the protocol.
- Any medical, psychiatric, occupational, or other condition that, in the judgment of
the investigator, would interfere with, or serve as a contraindication to, protocol
adherence, assessment of safety or reactogenicity, or a participant's ability to give
informed consent
- Psychiatric condition that precludes compliance with the protocol. Specifically
excluded are persons with psychoses within the past 3 years, ongoing risk for suicide,
or history of suicide attempt or gesture within the past 3 years.
- Current anti-tuberculosis (TB) prophylaxis or therapy
- Asthma other than mild or moderate, well-controlled asthma. More information on this
criterion can be found in the protocol.
- Diabetes mellitus type 1 or type 2, including cases controlled with diet alone. (Not
excluded: history of isolated gestational diabetes.)
- Thyroidectomy, or thyroid disease requiring medication during the last 12 months
- Hypertension: If a person has been found to have elevated blood pressure or
hypertension during screening or previously, exclude for blood pressure that is not
well controlled. Well-controlled blood pressure is defined as consistently less than
or equal to 140 mm Hg systolic and less than or equal to 90 mm Hg diastolic, with or
without medication, with only isolated, brief instances of higher readings, which must
be less than or equal to 150 mm Hg systolic and less than or equal to 100 mm Hg
diastolic. For these participants, blood pressure must be less than or equal to 140 mm
Hg systolic and less than or equal to 90 mm Hg diastolic at enrollment. If a person
has NOT been found to have elevated blood pressure or hypertension during screening or
previously, exclude for systolic blood pressure greater than or equal to 150 mm Hg at
enrollment or diastolic blood pressure greater than or equal to 100 mm Hg at
enrollment.
- History of myocarditis, pericarditis, cardiomyopathy, congestive heart failure with
permanent sequelae, clinically significant arrhythmia (including any arrhythmia
requiring medication, treatment, or clinical follow-up)
- ECG with clinically significant findings, or features that would interfere with the
assessment of myo/pericarditis, as determined by the contract ECG Lab, cardiologist,
or study clinician. More information on this criterion can be found in the protocol.
- Participants who have 2 or more of the following cardiac risk factors: (1) participant
report of history of elevated blood cholesterol defined as fasting low-density
lipoprotein (LDL) greater than 160 mg/dL; (2) first degree relative (e.g., mother,
father, brother, or sister) who had coronary artery disease before the age of 50
years); (3) current smoker; or (4) BMI greater than or equal to 35
- Allergy to eggs or egg products
- Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or
platelet disorder requiring special precautions)
- Malignancy (Not excluded: Participant who has had malignancy excised surgically and
who, in the investigator's estimation, has a reasonable assurance of sustained cure.
or who is unlikely to experience recurrence of malignancy during the period of the
study)
- Seizure disorder: History of seizure(s) within past three years. Also exclude if
participant has used medications in order to prevent or treat seizure(s) at any time
within the past 3 years.
- Asplenia: any condition resulting in the absence of a functional spleen
- History of hereditary angioedema, acquired angioedema, or idiopathic angioedema
|
